← All indications
Thrombocytopenia
A subnormal level of BLOOD PLATELETS.
Subtype terms (5)
More specific conditions that are subtypes of Thrombocytopenia in the MeSH hierarchy.
- Jacobsen Distal 11q Deletion Syndrome
- Kasabach-Merritt Syndrome
3 drugs approved
- Pseudothrombocytopenia
- Thrombocytopenia, Neonatal Alloimmune
5 drugs (3 approved, 2 experimental)
- Thrombotic Microangiopathies
9 drugs (5 approved, 4 experimental)
Drugs by status
Approved for this indication (16)
Phase 4 trials (19)
Phase 3 trials (23)
- decitabine
- methylprednisolone
- bu zhong yi qi tang, zhi xue tang, chuan xin lian kang yan pian mod, tian wang bu xin dan
- danaparoid sodium
- hydroxychloroquine
- Sovleplenib
- warfarin
- megakaryocytic progenitor cells
- belimumab
- acetylsalicylic acid
- mycophenolate
- cyclophosphamide
- dapsone
- vay736
- pn-152,243
- rivaroxaban
- tranexamic acid
- rigosertib
- rozanolixizumab
- efgartigimod
- papaya
- tqb3473
- orelabrutinib
Phase 2 trials (92)
- metformin
- lutetium (177Lu) vipivotide tetraxetan
- tioguanine
- mercaptopurine
- vitamin e
- autologous t cells
- bendamustine
- bpx-501
- busulfan
- irinotecan
- lenalidomide
- daclizumab
- danazol
- selinexor
- doxorubicin
- eculizumab
- entinostat
- gemcitabine
- tacrolimus
- naltrexone
- Filgrastim
- bc8
- leridistim
- leucovorin
- luspatercept
- ofatumumab
- vincristine
- oseltamivir
- panobinostat
- carboplatin
- +62 more
Phase 1 trials (21)
Organizations
Organization Involved with Phase 4 Indications (36)
- Canyon Pharmaceuticals
- Amgen
- Octapharma
- Genzyme
- Novartis
- Qidong Gaitianli Medicines Co., Ltd
- Sunshine Lake Pharma Co., Ltd.
- Xiamen Amoytop Biotech Co., Ltd.
- National Institute of Allergy and Infectious Diseases (NIAID)
- Huazhong University of Science and Technology
- Central South University
- Cornell University
- Etablissement Français du Sang
- Duke University
- D'Annunzio University of Chieti–Pescara
- Kunming Medical University
- Methodist Healthcare
- Shenyang Pharmaceutical University
- University of Palermo
- University of Tennessee
- University of Bern
- Assiut University
- Nanchang University
- Xiamen University
- Shandong University
- University of Basel
- Jiao Tong University
- Tianjin Medical University
- Henan Medical University
- University of Duesseldorf
- +6 more
Organization Involved with Phase 3 Indications (95)
- Eisai
- UCB
- Celgene
- Green Cross Corporation
- Aspen Pharmaceuticals
- Pfizer
- Shionogi
- Beijing Northland Biotech. Co., Ltd.
- CTI BioPharma
- Hamilton Health Sciences Corporation
- Hengrui Therapeutics, Inc.
- INC Research
- Kyowa Hakko Kirin
- SK Plasma Co., Ltd.
- Principia Biopharma, Inc.
- Terumo BCT
- National Cerebral and Cardiovascular Center
- National Heart, Lung, and Blood Institute (NHLBI)
- Ain Shams University
- Hebei University
- Anhui Medical University
- Baylor University
- Chang Gung University
- Harvard University
- University of Washington
- Guangzhou Medical University
- Hopital La Rabta
- Liaocheng People's Hospital
- Linyi People's Hospital
- Marshall University
- +65 more
Organization Involved with Phase 2 Indications (93)
- Takeda
- Millennium Pharmaceuticals
- Mitsubishi
- Bristol-Myers Squibb
- Sanofi
- Sanofi-Aventis
- Wyeth
- Akorn, Inc.
- BioMAS Ltd
- Cellphire, Inc.
- Oscotec Inc.
- Parexel
- Protalex, Inc.
- Red de Terapia Celular
- Rigel Pharmaceuticals
- Constant Pharmaceuticals
- Fondazione Progetto Ematologia
- Fondazione Telethon
- National Institutes of Health (NIH)
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- National Cancer Institute (NCI)
- National Center for Research Resources (NCRR)
- University of Roma La Sapienza
- University of Pittsburgh
- Associazione Qol-one
- Case Western Reserve University
- University of London
- China Academy of Chinese Medical Sciences
- Drexel University
- Emory University
- +63 more
Organization Involved with Phase 1 Indications (12)
Organization Involved with Other Experimental Indications (6)